Clinical Trial: Safety and Biodistribution of [68Ga]Ga DOTA-5G in Subjects With Metastatic Breast Cancer (BC)

U.S., Nov. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07915297) titled 'Safety and Biodistribution of [68Ga]Ga DOTA-5G in Subjects With Metastatic Breast Cancer (BC)' on Oct. 29.

Brief Summary: This is a prospective study using [68Ga]Ga DOTA-5G PET/CT imaging in patients diagnosed with metastatic breast cancer (BC).

Study Start Date: Nov. 15

Study Type: INTERVENTIONAL

Condition: Metastatic Breast Cancer

Intervention: DRUG: [68Ga]Ga DOTA-5G

Patients will be injected with up to 5 mCi of [68Ga]Ga DOTA-5G and imaged at 1 and 2 hours post injection

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Luminance Biosciences Inc

Published by HT Digital Content Services with permission from Health Daily Dige...